Semaglutide, the drug that regulates blood sugar and insulin, better known as Ozempic, has been the subject of analysis at the European Congress on Obesity. Doctors have analyzed its effect through data from a Step Teens clinical trial.
Almost half of the adolescents who used the drug reached normal weight or overweight and the use of the drug shows that liver damage derived from obesity can be reduced. Almost 60% of adults and one in three children are overweight, according to the World Health Organization.